KDM4B and neoplasm: We thus tested the KDM/Jumonji inhibitor JIB-04 [27] across a panel of breast cancer lines (Supplementary Figure 6) and found that the line most sensitive to JIB-04 was HCC1419, which is derived from a nonTN grade 2 tumor and expresses high levels of KDM4B (Figure 5B).